Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS: ziltivekimab versus placebo after acute myocardial infarction
2023-506876-28-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI), acute ST-segment elevation myocardial infarction (STEMI), Non-ST-segment elevation myocardial infarction (NSTEMI) and 1 more comparing ziltivekimab with placebo (2 arms). Primary endpoints: Time to first occurrence of 4-component MACE, Number of 4-component MACE events and 7 more. Planned start Aug 2024; status: authorised.
02
Drugs
ziltivekimab
03
Conditions
myocardial infarction (MI)acute ST-segment elevation myocardial infarction (STEMI)Non-ST-segment elevation myocardial infarction (NSTEMI)cardiac morbidity
Beyond the preview
Go deeper on 2023-506876-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506876-28-00.